A Fabry-kór a lizoszomális tárolási betegségek csoportjába tartozó, X-kromoszómához kötötten, recesszív módon öröklődő betegség, amely a globotriaozilceramid felhalmozódásához vezet a szervezet legkülönbözőbb szöveteiben. A betegség első tünetei többnyire gyermekkorban jelentkeznek, a progresszió során a betegek súlyos szervi károsodásokkal és korai halálozással számolhatnak. Elsősorban férfiak érintettek, azonban a betegség tüneteit heterozigóta nők esetében is megfigyelhetjük, de náluk a kórkép súlyossága változó, általában enyhébb lefolyású. Az enzimpótló kezelések megjelenése szükségessé tette, hogy részletes diagnosztikus és terápiás protokollt dolgozzunk ki. A jelen dolgozatban megjelenő ajánlásokat egy, a magyarországi Fabry-kóros betegek kezelésében részt vevő orvosokból, a diagnosztika területén dolgozó biológosukból és egyéb szakemberekből álló multidiszciplináris munkacsoport foglalta össze. A munkacsoport áttekintette a korábbi klinikai tanulmányokat, a publikált vizsgálatokat és a közelmúltban megjelent nemzetközi és nemzeti útmutatókat.
-
Constantin T., Rákóczi E., Ponyi A. és mtsai: Fabry–betegség – Diagnosztikai útmutató. Orv. Hetil., 2010, 151 , 243–249.
Ponyi A. , 'Fabry–betegség – Diagnosztikai útmutató ' (2010 ) 151 Orv. Hetil. : 243 -249 .
-
Eng, C. M., Germain, D. P., Banikazemi, M. és mtsai: Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet. Med., 2006, 8 , 539–548.
Banikazemi M. , 'Fabry disease: guidelines for the evaluation and management of multi-organ system involvement ' (2006 ) 8 Genet. Med. : 539 -548 .
-
Schaefer, R. M., Tylki-Szymanska, A., Hilz M. J.: Enzyme replacement therapy for Fabry disease: a systematic review of available evidence. Drugs, 2009, 69 , 2179–2205.
Hilz M. J. , 'Enzyme replacement therapy for Fabry disease: a systematic review of available evidence ' (2009 ) 69 Drugs : 2179 -2205 .
-
Connock, M., Juarez-Garcia, A., Frew, E. és mtsai: A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1. Health Technol. Assess., 2006, 10 , 113.
Frew E. , 'A systematic review of the clinical effectiveness and cost-effectiveness of enzyme replacement therapies for Fabry’s disease and mucopolysaccharidosis type 1 ' (2006 ) 10 Health Technol. Assess. : 113 -.
-
Desnick, R. J., Banikazemi M.: Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy. Nephrol. Ther., 2006, 2 , S172–S185.
Banikazemi M. , 'Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy ' (2006 ) 2 Nephrol. Ther. : S172 -S185 .
-
Clarke, L. A., Clarke, J. T., Sirrs, S. és mtsai: Fabry disease: Recommendations for diagnosis, management, and enzyme replacement therapy in Canada. 2005.
-
Hughes, D. A., Elliott, P. M., Lee, D. P. és mtsai: Guidelines for the diagnosis and management of Anderson-Fabry disease. London, 2003.
-
Desnick, R. J.: Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval. Expert. Opin. Biol. Ther., 2004, 4 , 1167–1176.
Desnick R. J. , 'Enzyme replacement therapy for Fabry disease: lessons from two alpha-galactosidase A orphan products and one FDA approval ' (2004 ) 4 Expert. Opin. Biol. Ther. : 1167 -1176 .
-
Schiffmann, R., Kopp, J. B., Austin, H. A. 3rd és mtsai: Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA, 2001, 285 , 2743–2749.
Austin H. A. , 'Enzyme replacement therapy in Fabry disease: a randomized controlled trial ' (2001 ) 285 JAMA : 2743 -2749 .
-
Eng, C. M., Guffon, N., Wilcox, W. R. és mtsai: Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease. N. Engl. J. Med., 2001, 345 , 9–16.
Wilcox W. R. , 'Safety and efficacy of recombinant human alpha-galactosidase A – replacement therapy in Fabry’s disease ' (2001 ) 345 N. Engl. J. Med. : 9 -16 .
-
Eng, C. M., Banikazemi, M., Gordon, R. E. és mtsai: A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet., 2001, 68 , 711–722.
Gordon R. E. , 'A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies ' (2001 ) 68 Am. J. Hum. Genet. : 711 -722 .
-
Wilcox, W. R., Banikazemi, M., Guffon, N. és mtsai: Long-term safety and efficacy of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet., 2004, 75 , 65–74.
Guffon N. , 'Long-term safety and efficacy of enzyme replacement therapy for Fabry disease ' (2004 ) 75 Am. J. Hum. Genet. : 65 -74 .
-
Hoffmann, B., Garcia de Lorenzo, A., Mehta, A. és mtsai: Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J. Med. Genet., 2005, 42 , 247–252.
Mehta A. , 'Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey) ' (2005 ) 42 J. Med. Genet. : 247 -252 .
-
Schiffmann, R., Floeter, M. K., Dambrosia, J. M. és mtsai: Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease. Muscle Nerve, 2003, 28 , 703–710.
Dambrosia J. M. , 'Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease ' (2003 ) 28 Muscle Nerve : 703 -710 .
-
Weidemann, F., Breunig, F., Beer, M. és mtsai: Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation, 2003, 108 , 1299–1301.
Beer M. , 'Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study ' (2003 ) 108 Circulation : 1299 -1301 .
-
Spinelli, L., Pisani, A., Sabbatini, M. és mtsai: Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin. Genet., 2004, 66 , 158–165.
Sabbatini M. , 'Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease ' (2004 ) 66 Clin. Genet. : 158 -165 .
-
Schiffmann, R., Ries, M., Timmons, M. és mtsai: Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting. Nephrol. Dial. Transplant., 2006, 21 , 345–354.
Timmons M. , 'Long-term therapy with agalsidase alfa for Fabry disease: safety and effects on renal function in a home infusion setting ' (2006 ) 21 Nephrol. Dial. Transplant. : 345 -354 .
-
Breunig, F., Weidemann, F., Strotmann, J. és mtsai: Clinical benefit of enzyme replacement therapy in Fabry disease. Kidney Int., 2006, 69 , 1216–1221.
Strotmann J. , 'Clinical benefit of enzyme replacement therapy in Fabry disease ' (2006 ) 69 Kidney Int. : 1216 -1221 .
-
Breunig, F., Wanner, C.: Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy. J. Nephrol., 2008, 21 , 32–37.
Wanner C. , 'Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy ' (2008 ) 21 J. Nephrol. : 32 -37 .
-
Banikazemi, M., Bultas, J., Waldek, S. és mtsai: Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann. Intern. Med., 2007, 146 , 77–86.
Waldek S. , 'Agalsidase-beta therapy for advanced Fabry disease: a randomized trial ' (2007 ) 146 Ann. Intern. Med. : 77 -86 .
-
Lidove, O., Joly, D., Barbey, F. és mtsai: Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature. Int. J. Clin. Pract., 2007, 61 , 293–302.
Barbey F. , 'Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature ' (2007 ) 61 Int. J. Clin. Pract. : 293 -302 .
-
Wanner, C.: Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies. Int. J. Clin. Pract., 2007, 61 , 1234–1235., author reply 5.
Wanner C. , 'Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies ' (2007 ) 61 Int. J. Clin. Pract. : 1234 -1235., author reply 5 .
-
Cho, M. E., Kopp, J. B.: Treatment of Fabry disease. In: Rose, B. D., Rush, J. M. (eds): UpToDate online. [Wellesley, Mass.] UpToDate, 2007.
-
Vedder, A. C., Linthorst, G. E., Houge, G. és mtsai: Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg. PLoS ONE, 2007, 2 , e598.
Houge G. , 'Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2 mg/kg ' (2007 ) 2 PLoS ONE : e598 -.
-
Vedder, A. C., Breunig, F., Donker-Koopman, W. E. és mtsai: Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3. Mol. Genet. Metab., 2008, 94 , 319–325.
Donker-Koopman W. E. , 'Treatment of Fabry disease with different dosing regimens of agalsidase: Effects on antibody formation and GL-3 ' (2008 ) 94 Mol. Genet. Metab. : 319 -325 .
-
Chimenti, C., Pieroni, M., Morgante, E. és mtsai: Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation, 2004, 110 , 1047–1053.
Morgante E. , 'Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy ' (2004 ) 110 Circulation : 1047 -1053 .
-
Conti, G., Sergi, B.: Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females. Acta Paediatr., 2003, 92 , 33–37., discussion 27.
Sergi B. , 'Auditory and vestibular findings in Fabry disease: a study of hemizygous males and heterozygous females ' (2003 ) 92 Acta Paediatr. : 33 -37., discussion 27 .
-
Deegan, P. B., Baehner, A. F., Barba Romero, M. A. és mtsai: Natural history of Fabry disease in females in the Fabry Outcome Survey. J. Med. Genet., 2006, 43 , 347–352.
Barba Romero M. A. , 'Natural history of Fabry disease in females in the Fabry Outcome Survey ' (2006 ) 43 J. Med. Genet. : 347 -352 .
-
Eng, C. M., Fletcher, J., Wilcox, W. R. és mtsai: Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis., 2007, 30 , 184–192.
Wilcox W. R. , 'Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry ' (2007 ) 30 J. Inherit. Metab. Dis. : 184 -192 .
-
Fellgiebel, A., Muller, M. J., Mazanek, M. és mtsai: White matter lesion severity in male and female patients with Fabry disease. Neurology, 2005, 65 , 600–602.
Mazanek M. , 'White matter lesion severity in male and female patients with Fabry disease ' (2005 ) 65 Neurology : 600 -602 .
-
Ortiz, A., Oliveira, J. P., Waldek, S. és mtsai: Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy. Nephrol. Dial. Transplant., 2008, 23 , 1600–1607.
Waldek S. , 'Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy ' (2008 ) 23 Nephrol. Dial. Transplant. : 1600 -1607 .
-
Wang, R. Y., Lelis, A., Mirocha, J. és mtsa: Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet. Med., 2007, 9 , 34–45.
Mirocha J. , 'Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life ' (2007 ) 9 Genet. Med. : 34 -45 .
-
Wilcox, W. R., Oliveira, J. P., Hopkin, R. J. és mtsai: Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry. Mol. Genet. Metab., 2008, 93 , 112–128.
Hopkin R. J. , 'Females with Fabry disease frequently have major organ involvement: Lessons from the Fabry Registry ' (2008 ) 93 Mol. Genet. Metab. : 112 -128 .
-
Baehner, F., Kampmann, C., Whybra, C. és mtsai: Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study. J. Inherit. Metab. Dis., 2003, 26 , 617–627.
Whybra C. , 'Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study ' (2003 ) 26 J. Inherit. Metab. Dis. : 617 -627 .
-
Elleder, M., Poupetova, H., Kozich, V.: Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I. Cesk. Patol., 1998, 34 , 7–12.
Kozich V. , 'Fetal pathology in Fabry’s disease and mucopolysaccharidosis type I ' (1998 ) 34 Cesk. Patol. : 7 -12 .
-
Mehta, A., Ricci, R., Widmer, U. és mtsai: Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest., 2004, 34 , 236–242.
Widmer U. , 'Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey ' (2004 ) 34 Eur. J. Clin. Invest. : 236 -242 .
-
Desnick, R. J., Brady, R. O.: Fabry disease in childhood. J. Pediatr., 2004, 144 , S20–S26.
Brady R. O. , 'Fabry disease in childhood ' (2004 ) 144 J. Pediatr. : S20 -S26 .
-
Ramaswami, U., Whybra, C., Parini, R. és mtsai: Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey. Acta Paediatr., 2006, 95 , 86–92.
Parini R. , 'Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey ' (2006 ) 95 Acta Paediatr. : 86 -92 .
-
Shah, J. S., Elliott, P. M.: Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatr., 2005, 94 , 11–14; discussion 9–10.
Elliott P. M. , 'Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy ' (2005 ) 94 Acta Paediatr. : 11 -14; discussion 9–10 .
-
Hughes, D. A., Elliott, P. M., Shah, J. és mtsai: Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa. Heart, 2008, 94 , 153–158.
Shah J. , 'Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase-alfa ' (2008 ) 94 Heart : 153 -158 .
-
Hoffmann, B., Beck, M., Sunder-Plassmann, G. és mtsai: Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey. Clin. J. Pain, 2007, 23 , 535–542.
Sunder-Plassmann G. , 'Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy – a retrospective analysis from the Fabry Outcome Survey ' (2007 ) 23 Clin. J. Pain : 535 -542 .
-
Bierer, G., Balfe, D., Wilcox, W. R. és mtsa: Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease. J. Inherit. Metab. Dis., 2006, 29 , 572–579.
Wilcox W. R. , 'Improvement in serial cardiopulmonary exercise testing following enzyme replacement therapy in Fabry disease ' (2006 ) 29 J. Inherit. Metab. Dis. : 572 -579 .
-
Ramaswami, U., Wendt, S., Pintos-Morell, G. és mtsai: Enzyme replacement therapy with agalsidase alfa in children with Fabry disease. Acta Paediatr., 2007, 96 , 122–127.
Pintos-Morell G. , 'Enzyme replacement therapy with agalsidase alfa in children with Fabry disease ' (2007 ) 96 Acta Paediatr. : 122 -127 .
-
Ries, M., Clarke, J. T., Whybra, C. és mtsai: Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease. Pediatrics, 2006, 118 , 924–932.
Whybra C. , 'Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease ' (2006 ) 118 Pediatrics : 924 -932 .
-
Askari, H., Kaneski, C. R., Semino-Mora, C. és mtsai: Cellular and tissue localization of globotriaosylceramide in Fabry disease. Virchows Arch., 2007, 451 , 823–834.
Semino-Mora C. , 'Cellular and tissue localization of globotriaosylceramide in Fabry disease ' (2007 ) 451 Virchows Arch. : 823 -834 .
-
Orteu, C. H., Jansen, T., Lidove, O. és mtsai: Fabry disease and the skin: data from FOS, the Fabry outcome survey. Br. J. Dermatol., 2007, 157 , 331–337.
Lidove O. , 'Fabry disease and the skin: data from FOS, the Fabry outcome survey ' (2007 ) 157 Br. J. Dermatol. : 331 -337 .
-
Sodi, A., Ioannidis, A. S., Mehta, A. és mtsai: Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey. Br. J. Ophthalmol., 2007, 91 , 210–214.
Mehta A. , 'Ocular manifestations of Fabry’s disease: data from the Fabry Outcome Survey ' (2007 ) 91 Br. J. Ophthalmol. : 210 -214 .
-
Mastropasqua, L., Nubile, M., Lanzini, M. és mtsai: Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study. Am. J. Ophthalmol., 2006, 141 , 709–718.
Lanzini M. , 'Corneal and conjunctival manifestations in Fabry disease: in vivo confocal microscopy study ' (2006 ) 141 Am. J. Ophthalmol. : 709 -718 .
-
Nguyen, T. T., Gin, T., Nicholls, K. és mtsai: Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre. Clin. Experiment. Ophthalmol., 2005, 33 , 164–168.
Nicholls K. , 'Ophthalmological manifestations of Fabry disease: a survey of patients at the Royal Melbourne Fabry Disease Treatment Centre ' (2005 ) 33 Clin. Experiment. Ophthalmol. : 164 -168 .
-
Cho, M. E., Kopp, J. B.: Clinical features and dignosis of Fabry disease. In: Rose, B. D., Rush, J. M. (eds): UpToDate online. [Wellesley, Mass.] UpToDate, 2007.
-
Zhang, S. H., Liu, Z. H., Zeng, C. H. és mtsai: Fabry disease: renal biopsy-proven cases from China. J. Nephrol., 2007, 20 , 716–726.
Zeng C. H. , 'Fabry disease: renal biopsy-proven cases from China ' (2007 ) 20 J. Nephrol. : 716 -726 .
-
Warnock, D. G.: Fabry disease: diagnosis and management, with emphasis on the renal manifestations. Curr. Opin. Nephrol. Hypertens., 2005, 14 , 87–95.
Warnock D. G. , 'Fabry disease: diagnosis and management, with emphasis on the renal manifestations ' (2005 ) 14 Curr. Opin. Nephrol. Hypertens. : 87 -95 .
-
Thurberg, B. L., Rennke, H., Colvin, R. B. és mtsai: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int., 2002, 62 , 1933–1946.
Colvin R. B. , 'Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy ' (2002 ) 62 Kidney Int. : 1933 -1946 .
-
Breunig, F., Weidemann, F., Beer, M. és mtsai: Fabry disease: diagnosis and treatment. Kidney Int., 2003, 63 , S181–S185.
Beer M. , 'Fabry disease: diagnosis and treatment ' (2003 ) 63 Kidney Int. : S181 -S185 .
-
Warnock, D. G., West, M. L.: Diagnosis and management of kidney involvement in Fabry disease. Adv. Chronic. Kidney Dis., 2006, 13 , 138–147.
West M. L. , 'Diagnosis and management of kidney involvement in Fabry disease ' (2006 ) 13 Adv. Chronic. Kidney Dis. : 138 -147 .
-
Warnock, D. G.: Enzyme replacement therapy and Fabry kidney disease: quo vadis? J. Am. Soc. Nephrol., 2007, 18 , 1368–1370.
Warnock D. G. , 'Enzyme replacement therapy and Fabry kidney disease: quo vadis? ' (2007 ) 18 J. Am. Soc. Nephrol. : 1368 -1370 .
-
Tahir, H., Jackson, L. L., Warnock, D. G. és mtsai: Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta. J. Am. Soc. Nephrol., 2007, 18 , 2609–2617.
Warnock D. G. , 'Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta ' (2007 ) 18 J. Am. Soc. Nephrol. : 2609 -2617 .
-
Wanner, C., Breunig, F.: Fabry nephropathy and the case for adjunctive renal therapy. J. Am. Soc. Nephrol., 2007, 18 , 2426–2428.
Breunig F. , 'Fabry nephropathy and the case for adjunctive renal therapy ' (2007 ) 18 J. Am. Soc. Nephrol. : 2426 -2428 .
-
Branton, M. H., Schiffmann, R., Sabnis, S. G. és mtsai: Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine, 2002, 81 , 122–138.
Sabnis S. G. , 'Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course ' (2002 ) 81 Medicine : 122 -138 .
-
Kleinert, J., Dehout, F., Schwarting, A. és mtsai: Prevalence of uncontrolled hypertension in patients with Fabry disease. Am. J. Hypertens., 2006, 19 , 782–787.
Schwarting A. , 'Prevalence of uncontrolled hypertension in patients with Fabry disease ' (2006 ) 19 Am. J. Hypertens. : 782 -787 .
-
Gantenbein, H., Bruder, E., Burger, H. R. és mtsai: Recurrence of Fabry’s disease in a renal allograft 14 years after transplantation. Nephrol. Dial. Transplant., 1995, 10 , 287–289.
Burger H. R. , 'Recurrence of Fabry’s disease in a renal allograft 14 years after transplantation ' (1995 ) 10 Nephrol. Dial. Transplant. : 287 -289 .
-
Mignani, R., Feriozzi, S., Pisani, A. és mtsai: Agalsidase Therapy in Patients with Fabry Disease on Renal Replacement Therapy: a Nationwide Study in Italy. Nephrol. Dial. Transplant., 2008, 23 , 1628–1635.
Pisani A. , 'Agalsidase Therapy in Patients with Fabry Disease on Renal Replacement Therapy: a Nationwide Study in Italy ' (2008 ) 23 Nephrol. Dial. Transplant. : 1628 -1635 .
-
De Backer, J., Matthys, D., Gillebert, T. C. és mtsai: The use of tissue doppler imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies. Eur. J. Echocardiogr., 2005, 6 , 243–250.
Gillebert T. C. , 'The use of tissue doppler imaging for the assessment of changes in myocardial structure and function in inherited cardiomyopathies ' (2005 ) 6 Eur. J. Echocardiogr. : 243 -250 .
-
Kampmann, C., Wiethoff, C. M., Martin, C. és mtsai: Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr., 2002, 91 , 21–27.
Martin C. , 'Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy ' (2002 ) 91 Acta Paediatr. : 21 -27 .
-
Hughes, M., Lip, G. Y.: Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb. Haemost., 2008, 99 , 295–304.
Lip G. Y. , 'Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data ' (2008 ) 99 Thromb. Haemost. : 295 -304 .
-
Padanilam, B. J., Prystowsky, E. N.: Atrial fibrillation: goals of therapy and management strategies to achieve the goals. Med. Clin. North Am., 2008, 92 , 217–235.
Prystowsky E. N. , 'Atrial fibrillation: goals of therapy and management strategies to achieve the goals ' (2008 ) 92 Med. Clin. North Am. : 217 -235 .
-
Waldo, A. L.: Anticoagulation: stroke prevention in patients with atrial fibrillation. Med. Clin. North Am., 2008, 92 , 143–159.
Waldo A. L. , 'Anticoagulation: stroke prevention in patients with atrial fibrillation ' (2008 ) 92 Med. Clin. North Am. : 143 -159 .
-
Strotmann, J., Weidemann, F., Breunig, F. és mtsai: Morbus Fabry of the heart. Why should cardiologists care? Z. Kardiol., 2005, 94 , 557–563.
Breunig F. , 'Morbus Fabry of the heart. Why should cardiologists care? ' (2005 ) 94 Z. Kardiol. : 557 -563 .
-
Pieroni, M., Chimenti, C., De Cobelli, F. és mtsai: Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J. Am. Coll. Cardiol., 2006, 47 , 1663–161.
Cobelli F. , 'Fabry’s disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization ' (2006 ) 47 J. Am. Coll. Cardiol. : 1663 -161 .
-
Imbriaco, M., Spinelli, L., Cuocolo, A. és mtsai: MRI characterization of myocardial tissue in patients with Fabry’s disease. AJR Am. J. Roentgenol., 2007, 188 , 850–853.
Cuocolo A. , 'MRI characterization of myocardial tissue in patients with Fabry’s disease ' (2007 ) 188 AJR Am. J. Roentgenol. : 850 -853 .
-
Sechtem, U., Mahrholdt, H., Vogelsberg, H.: Cardiac magnetic resonance in myocardial disease. Heart, 2007, 93 , 1520–1527.
Vogelsberg H. , 'Cardiac magnetic resonance in myocardial disease ' (2007 ) 93 Heart : 1520 -1527 .
-
Moon, J. C., Sheppard, M., Reed, E. és mtsai: The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J. Cardiovasc. Magn. Reson., 2006, 8 , 479–482.
Reed E. , 'The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease ' (2006 ) 8 J. Cardiovasc. Magn. Reson. : 479 -482 .
-
Beer, M., Weidemann, F., Breunig, F. és mtsai: Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy. Am. J. Cardiol., 2006, 97 , 1515–1518.
Breunig F. , 'Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry’s cardiomyopathy ' (2006 ) 97 Am. J. Cardiol. : 1515 -1518 .
-
Horowitz, S. H.: The diagnostic workup of patients with neuropathic pain. Med. Clin. North Am., 2007, 91 , 21–30.
Horowitz S. H. , 'The diagnostic workup of patients with neuropathic pain ' (2007 ) 91 Med. Clin. North Am. : 21 -30 .
-
Lacomis, D., Roeske-Anderson, L., Mathie, L.: Neuropathy and Fabry’s disease. Muscle Nerve, 2005, 31 , 102–107.
Mathie L. , 'Neuropathy and Fabry’s disease ' (2005 ) 31 Muscle Nerve : 102 -107 .
-
Gomes, I., Nora, D. B., Becker, J. és mtsai: Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease. J. Neurol. Sci., 2003, 214 , 21–25.
Becker J. , 'Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease ' (2003 ) 214 J. Neurol. Sci. : 21 -25 .
-
Ginsberg, L., Manara, R., Valentine, A. R. és mtsai: Magnetic resonance imaging changes in Fabry disease. Acta Paediatr., 2006, 95 , 57–62.
Valentine A. R. , 'Magnetic resonance imaging changes in Fabry disease ' (2006 ) 95 Acta Paediatr. : 57 -62 .
-
Lidove, O., Klein, I., Lelievre, J. D. és mtsai: Imaging features of Fabry disease. AJR Am. J. Roentgenol., 2006, 186 , 1184–1191.
Lelievre J. D. , 'Imaging features of Fabry disease ' (2006 ) 186 AJR Am. J. Roentgenol. : 1184 -1191 .
-
Moore, D. F., Ye, F., Schiffmann, R. és mtsa: Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. AJNR Am. J. Neuroradiol., 2003, 24 , 1096–1101.
Schiffmann R. , 'Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease ' (2003 ) 24 AJNR Am. J. Neuroradiol. : 1096 -1101 .
-
Moore, D. F., Kaneski, C. R., Askari, H. és mtsa: The cerebral vasculopathy of Fabry disease. J. Neurol. Sci., 2007, 257 , 258–263.
Askari H. , 'The cerebral vasculopathy of Fabry disease ' (2007 ) 257 J. Neurol. Sci. : 258 -263 .
-
Garzuly, F., Maródi, L., Erdős, M. és mtsai: Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the alpha-galactosidase A gene. Brain, 2005, 128 , 2078–2083.
Erdős M. , 'Megadolichobasilar anomaly with thrombosis in a family with Fabry’s disease and a novel mutation in the alpha-galactosidase A gene ' (2005 ) 128 Brain : 2078 -2083 .
-
Rolfs, A., Bottcher, T., Zschiesche, M. és mtsai: Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet, 2005, 366 , 1794–1796.
Zschiesche M. , 'Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study ' (2005 ) 366 Lancet : 1794 -1796 .
-
Mehta, A., Ginsberg, L.: Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr., 2005, 94 , 24–27.; discussion 9–10.
Ginsberg L. , 'Natural history of the cerebrovascular complications of Fabry disease ' (2005 ) 94 Acta Paediatr. : 24 -27.; discussion 9–10 .
-
Barbey, F., Brakch, N., Linhart, A. és mtsai: Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease. Acta Paediatr., 2006, 95 , 63–68.
Linhart A. , 'Increased carotid intima-media thickness in the absence of atherosclerotic plaques in an adult population with Fabry disease ' (2006 ) 95 Acta Paediatr. : 63 -68 .
-
Rincon, F., Sacco, R. L.: Secondary stroke prevention. J. Cardiovasc. Nurs., 2008, 23 , 34–41. Quiz 2-3.
Sacco R. L. , 'Secondary stroke prevention ' (2008 ) 23 J. Cardiovasc. Nurs. : 34 -41. Quiz 2-3 .
-
Romero, J. R.: Prevention of ischemic stroke: overview of traditional risk factors. Curr. Drug. Targets, 2007, 8 , 794–801.
Romero J. R. , 'Prevention of ischemic stroke: overview of traditional risk factors ' (2007 ) 8 Curr. Drug. Targets : 794 -801 .
-
Goldstein, L. B., Adams, R., Alberts, M. J. és mtsai: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation, 2006, 113 , e873–e923.
Alberts M. J. , 'Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group ' (2006 ) 113 Circulation : e873 -e923 .
-
Goldstein, L. B., Adams, R., Alberts, M. J. és mtsai: Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline. Stroke, 2006, 37 , 1583–1633.
Alberts M. J. , 'Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: the American Academy of Neurology affirms the value of this guideline ' (2006 ) 37 Stroke : 1583 -1633 .
-
Hegemann, S., Hajioff, D., Conti, G. és mtsai: Hearing loss in Fabry disease: data from the Fabry Outcome Survey. Eur. J. Clin. Invest., 2006, 36 , 654–662.
Conti G. , 'Hearing loss in Fabry disease: data from the Fabry Outcome Survey ' (2006 ) 36 Eur. J. Clin. Invest. : 654 -662 .
-
Hoffmann, B., Keshav, S.: Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment. Acta Paediatr., 2007, 96 , 84–86.
Keshav S. , 'Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment ' (2007 ) 96 Acta Paediatr. : 84 -86 .
-
Hoffmann, B., Schwarz, M., Mehta, A. és mtsa: Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin. Gastroenterol. Hepatol., 2007, 5 , 1447–1453.
Mehta A. , 'Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy ' (2007 ) 5 Clin. Gastroenterol. Hepatol. : 1447 -1453 .
-
Feriozzi, S., Torre, E. S., Ranalli, T. V. és mtsai: A diagnosis of Fabry gastrointestinal disease by chance: a case report. Eur. J. Gastroenterol. Hepatol., 2007, 19 , 163–165.
Ranalli T. V. , 'A diagnosis of Fabry gastrointestinal disease by chance: a case report ' (2007 ) 19 Eur. J. Gastroenterol. Hepatol. : 163 -165 .
-
Magage, S., Lubanda, J. C., Susa, Z. és mtsai: Natural history of the respiratory involvement in Anderson-Fabry disease. J. Inherit. Metab. Dis., 2007, 30 , 790–799.
Susa Z. , 'Natural history of the respiratory involvement in Anderson-Fabry disease ' (2007 ) 30 J. Inherit. Metab. Dis. : 790 -799 .
-
Mersebach, H., Johansson, J. O., Rasmussen, A. K. és mtsai: Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density. Genet. Med., 2007, 9 , 812–818.
Rasmussen A. K. , 'Osteopenia: a common aspect of Fabry disease. Predictors of bone mineral density ' (2007 ) 9 Genet. Med. : 812 -818 .
Főszerkesztő - Editor-in-Chief:
Zoltán PAPP (professor emeritus, Semmelweis Egyetem, Szülészeti és Nőgyógyászati Klinika, Budapest)
Read the professional career of Zoltán PAPP HERE.
All scientific publications of Zoltán PAPP are collected in the Hungarian Scientific Bibliography.
Főszerkesztő-helyettesek - Assistant Editors-in-Chief:
- Erzsébet FEHÉR (professor emeritus, Semmelweis Egyetem, Anatómiai, Szövet- és Fejlődéstani Intézet)
- Krisztina HAGYMÁSI (egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)
Főmunkatársak - Senior Editorial Specialists:
- László KISS (a Debreceni Egyetem habilitált doktora)
- Gabriella LENGYEL (ny. egyetemi docens, Semmelweis Egyetem, I. Sebészeti és Intervenciós Gasztroenterológiai Klinika, Budapest)
- Alajos PÁR (professor emeritus, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)
A Szerkesztőbizottság tagjai – Members of the Editorial Board:
- Péter ANDRÉKA (főigazgató, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
- Géza ÁCS Jr. (egyetemi tanár Floridában)
- Csaba BALÁZS (egyetemi tanár, Budai Endokrinközpont, Budapest)
- Péter BENCSIK (volt folyóirat-kiadás vezető, Akadémiai Kiadó, Budapest)
- Zoltán BENYÓ (egyetemi tanár, Semmelweis Egyetem, Transzlációs Medicina Intézet, Budapest)
- Dániel BERECZKI (egyetemi tanár, Semmelweis Egyetem, Neurológiai Klinika, Budapest)
- Anna BLÁZOVICS (professor emeritus, Semmelweis Egyetem, Farmakognóziai Intézet, Budapest)
- Elek DINYA (professor emeritus, biostatisztikus, Semmelweis Egyetem, Budapest)
- Attila DOBOZY (professor emeritus, Szegedi Tudományegyetem, Bőrgyógyászati Klinika, Szeged)
- András FALUS (professor emeritus, Semmelweis Egyetem, Genetikai, Sejt- és Immunbiológiai Intézet, Budapest)
- Csaba FARSANG (egyetemi tanár, Szent Imre Oktató Kórház, Belgyógyászati Osztály, Budapest)
- János FAZAKAS (egyetemi docens, Semmelweis Egyetem, Transzplantációs és Sebészeti Klinika, Budapest)
- Béla FÜLESDI (egyetemi tanár, Debreceni Egyetem, Aneszteziológiai és Intenzív Terápiás Klinika, Debrecen)
- Beáta GASZTONYI (egyetemi magántanár, kórházi főorvos, Zala Megyei Kórház, Belgyógyászat, Zalaegerszeg)
- István GERGELY (egyetemi docens, Marosvásárhelyi Orvosi és Gyógyszerészeti Egyetem, Románia)
- Judit GERVAIN (osztályvezető főorvos, Fejér Megyei Szent György Kórház, Belgyógyászat, Székesfehérvár)
- Béla GÖMÖR (professor emeritus, Budai Irgalmasrendi Kórház, Reumatológiai Osztály, Budapest)
- László GULÁCSI (egyetemi tanár, Óbudai Egyetem, Egészségügyi Közgazdaságtan Tanszék, Budapest)
- János HANKISS (professor emeritus, Markusovszky Lajos Oktató Kórház, Belgyógyászati Osztály, Szombathely)
- Örs Péter HORVÁTH (professor emeritus, Pécsi Tudományegyetem, Sebészeti Klinika, Pécs)
- Béla HUNYADY (egyetemi tanár, Somogy Megyei Kaposi Mór Kórház, Belgyógyászat, Kaposvár)
- Péter IGAZ (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
- Ferenc JAKAB (c. egyetemi tanár, Uzsoki Utcai Kórház, Sebészet, Budapest)
- András JÁNOSI (c. egyetemi tanár, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
- György JERMENDY (egyetemi tanár, Bajcsy-Zsilinszky Kórház, Belgyógyászat, Budapest)
- László KALABAY (egyetemi tanár, Semmelweis Egyetem, Családorvosi Tanszék, Budapest)
- János KAPPELMAYER (egyetemi tanár, Debreceni Egyetem, Laboratóriumi Medicina Intézet, Debrecen)
- Éva KELLER (ny. egyetemi tanár, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
- Mátyás KELTAI (ny. egyetemi docens, Gottsegen György Országos Kardiovaszkuláris Intézet, Nemzeti Szívinfartkus Regiszter, Budapest)
- András KISS (egyetemi tanár, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
- László KÓBORI (egyetemi tanár, Semmelweis Egyetem, Transzplantációs és Sebészeti Klinika, Budapest)
- Lajos KULLMANN (ny. egyetemi tanár, Országos Rehabilitációs Intézet, Budapest)
- Emese MEZŐSI (egyetemi tanár, Pécsi Tudományegyetem, I. Belgyógyászati Klinika, Pécs)
- József MOLNÁR (professor emeritus, Szegedi Tudományegyetem, Mikrobiológiai és Immunológiai Intézet, Szeged)
- Péter MOLNÁR (professor emeritus, Debreceni Egyetem, Magatartástudományi Intézet, Debrecen)
- Györgyi MŰZES (egyetemi docens, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Bálint NAGY (egyetemi tanár, Debreceni Egyetem, Humángenetikai Tanszék, Debrecen)
- Endre NAGY (egyetemi tanár, Debreceni Egyetem, Belgyógyászati Intézet, Debrecen)
- Péter NAGY (egyetemi tanár, Semmelweis Egyetem, I. Patológiai és Kísérleti Rákkutató Intézet, Budapest)
- Viktor NAGY (főorvos, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Zoltán Zsolt NAGY (egyetemi tanár, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
- Balázs NEMES (egyetemi docens, Debreceni Egyetem, Transzplantációs Tanszék, Debrecen)
- Attila PATÓCS (tudományos főmunkatárs, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Gabriella PÁR (egyetemi docens, Pécsi Tudományegyetem, I. Belgyógyászati Klinika)
- György PFLIEGLER (egyetemi tanár, Debreceni Egyetem, Ritka Betegségek Tanszéke, Debrecen)
- István RÁCZ (egyetemi tanár, főorvos, Petz Aladár Megyei Oktató Kórház, Belgyógyászat, Győr)
- Imre ROMICS (professor emeritus, Semmelweis Egyetem, Urológiai Klinika, Budapest)
- László Jr. ROMICS (Angliában dolgozik)
- Imre RURIK (egyetemi tanár, Debreceni Egyetem, Családorvosi és Foglalkozás-egészségügyi Tanszék, Debrecen)
- Zsuzsa SCHAFF (professor emeritus, Semmelweis Egyetem, II. Patológiai Intézet, Budapest)
- Péter SCHMIDT (házi gyermekorvos, Győr)
- Kornél SIMON (ny. osztályvezető főorvos, Siófoki Kórház, Belgyógyászat, Siófok)
- Gábor SIMONYI (vezető főorvos, Szent Imre Kórház, Anyagcsere Központ, Budapest)
- Gábor Márk SOMFAI (egyetemi docens, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
- Anikó SOMOGYI (ny. egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Péter SÓTONYI (professor emeritus, Semmelweis Egyetem, Igazságügyi és Biztosítás-orvostani Intézet, Budapest)
- Péter Jr. SÓTONYI (egyetemi tanár, Semmelweis Egyetem, Városmajori Szív- és Érsebészeti Klinika, Budapest)
- Ildikó SÜVEGES (professor emeritus, Semmelweis Egyetem, Szemészeti Klinika, Budapest)
- György SZABÓ (professor emeritus, Semmelweis Egyetem, Arc-Állcsont-Szájsebészeti és Fogászati Klinika, Budapest)
- Ferenc SZALAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
- Miklós SZENDRŐI (professor emeritus, Semmelweis Egyetem, Ortopédiai Klinika, Budapest)
- István SZILVÁSI (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Miklós TÓTH (egyetemi tanár, Semmelweis Egyetem, Belgyógyászati és Onkológiai Klinika, Budapest)
- László TRINGER (professor emeritus, Semmelweis Egyetem, Pszichiátriai és Pszichoterápiás Klinika, Budapest)
- Tivadar TULASSAY (professor emeritus, Semmelweis Egyetem, I. Gyermekgyógyászati Klinika, Budapest)
- Zsolt TULASSAY (professor emeritus, Semmelweis Egyetem, Belgyógyászati és Hematológiai Klinika, Budapest)
- Lívia VASAS (ny. könyvtárigazgató, Semmelweis Egyetem, Központi Könyvtár, Budapest)
- Barna VÁSÁRHELYI (egyetemi tanár, Semmelweis Egyetem, Laboratóriumi Medicina Intézet, Budapest)
- László VÉCSEI (professor emeritus, Szegedi Tudományegyetem, Neurológiai Klinika, Szeged)
- Gábor WINKLER (egyetemi tanár, Szent János Kórház, Belgyógyászati Osztály, Budapest)
Nemzetközi szerkesztőbizottság - International Editorial Board:
- Elnök/President Péter SÓTONYI (Budapest)
- Ernest ADEGHATE (Al Ain)
- Ferenc ANTONI (Edinburgh)
- Maciej BANACH (Łódź)
- Klára BERENCSI (Rosemont)
- Angelo BIGNAMINI (Milano)
- Anupam BISHAYEE (Signal Hill)
- Hubert E. BLUM (Freiburg)
- G. László BOROS (Los Angeles)
- Frank A. CHERVENAK (New York)
- Meinhard CLASSEN (München)
- József DÉZSY (Wien)
- Peter ECKL (Salzburg)
- Péter FERENCI (Wien)
- Madelaine HAHN (Erlangen)
- S. Tamás ILLÉS (Bruxelles)
- Michael KIDD (Toronto)
- Andrzej KOKOSZKA (Warsaw)
- Márta KORBONITS (London)
- Asim KURJAK (Zagreb)
- Manfred MAIER (Wien)
- Neil MCINTYRE (London)
- Lajos OKOLICSÁNYI (Padova)
- Amado Salvador PENA (Amsterdam)
- Guliano RAMADORI (Goettingen)
- Olivér RÁCZ (Košice)
- Roberto ROMERO (Detroit)
- Rainer SCHÖFL (Linz)
- Zvi VERED (Tel Aviv)
- Josef VESELY (Olomouc)
- Ákos ZAHÁR (Hamburg)
Akadémiai Kiadó Zrt. 1117 Budapest
Budafoki út 187-189.
A épület, III. emelet
Phone: (+36 1) 464 8235
Email: orvosihetilap@akademiai.hu
- Web of Science SCIE
- Scopus
- Medline
- CABELLS Journalytics
| 2021 | |
|---|---|
| Web of Science | |
| Total Cites WoS |
1386 |
| Journal Impact Factor | 0,707 |
| Rank by Impact Factor | Medicine, General & Internal 158/172 |
| Impact Factor without Journal Self Cites |
0,407 |
| 5 Year Impact Factor |
0,572 |
| Journal Citation Indicator | 0,15 |
| Rank by Journal Citation Indicator | Medicine, General & Internal 214/329 |
| Scimago | |
| Scimago H-index |
23 |
| Scimago Journal Rank |
0,184 |
| Scimago Quartile Score | Medicine (miscellaneous) (Q4) |
| Scopus | |
| Scopus Cite Score |
0,9 |
| Scopus CIte Score Rank |
General Medicine 528/826 (Q3) |
| Scopus SNIP |
0,242 |
| 2020 | |
| Total Cites | 1277 |
| WoS | |
| Journal Impact Factor |
0,540 |
| Rank by | Medicine, General & Internal 155/169 (Q4) |
| Impact Factor | |
| Impact Factor | 0,310 |
| without | |
| Journal Self Cites | |
| 5 Year | 0,461 |
| Impact Factor | |
| Journal | 0,17 |
| Citation Indicator | |
| Rank by Journal | Medicine, General & Internal 203/313 (Q4) |
| Citation Indicator | |
| Citable | 261 |
| Items | |
| Total | 229 |
| Articles | |
| Total | 32 |
| Reviews | |
| Scimago | 21 |
| H-index | |
| Scimago | 0,176 |
| Journal Rank | |
| Scimago | Medicine (miscellaneous) Q4 |
| Quartile Score | |
| Scopus | 921/1187=0,8 |
| Scite Score | |
| Scopus | General Medicine 494/793 (Q3) |
| Scite Score Rank | |
| Scopus | 0,283 |
| SNIP | |
| Days from | 28 |
| submission | |
| to acceptance | |
| Days from | 114 |
| acceptance | |
| to publication | |
| Acceptance | 72% |
| Rate |
| 2019 | |
|---|---|
| Total Cites WoS |
1 085 |
| Impact Factor | 0,497 |
| Impact Factor without Journal Self Cites |
0,212 |
| 5 Year Impact Factor |
0,396 |
| Immediacy Index |
0,126 |
| Citable Items |
247 |
| Total Articles |
176 |
| Total Reviews |
71 |
| Cited Half-Life |
6,1 |
| Citing Half-Life |
7,3 |
| Eigenfactor Score |
0,00071 |
| Article Influence Score |
0,045 |
| % Articles in Citable Items |
71,26 |
| Normalized Eigenfactor |
0,08759 |
| Average IF Percentile |
10,606 |
| Scimago H-index |
20 |
| Scimago Journal Rank |
0,176 |
| Scopus Scite Score |
864/1178=0,4 |
| Scopus Scite Score Rank |
General Medicine 267/529 (Q3) |
| Scopus SNIP |
0,254 |
| Acceptance Rate |
73% |
| Orvosi Hetilap | |
|---|---|
| Publication Model | Hybrid |
| Submission Fee | none |
| Article Processing Charge | 900 EUR/article |
| Printed Color Illustrations | 20 EUR (or 5000 HUF) + VAT / piece |
| Regional discounts on country of the funding agency | World Bank Lower-middle-income economies: 50% World Bank Low-income economies: 100% |
| Further Discounts | Editorial Board / Advisory Board members: 50% Corresponding authors, affiliated to an EISZ member institution subscribing to the journal package of Akadémiai Kiadó: 100% |
| Subscription fee 2023 | Online subsscription: 858 EUR / 1157 USD Print + online subscription: 975 EUR / 1352 USD |
| Subscription Information | Online subscribers are entitled access to all back issues published by Akadémiai Kiadó for each title for the duration of the subscription, as well as Online First content for the subscribed content. |
| Purchase per Title | Individual articles are sold on the displayed price. |
| Orvosi Hetilap | |
|---|---|
| Language | Hungarian |
| Size | A4 |
| Year of Foundation |
1857 |
| Volumes per Year |
1 |
| Issues per Year |
52 |
| Founder | Markusovszky Lajos Alapítvány -- Lajos Markusovszky Foundation |
| Founder's Address |
H-1088 Budapest, Szentkriályi u. 46. |
| Publisher | Akadémiai Kiadó |
| Publisher's Address |
H-1117 Budapest, Hungary 1516 Budapest, PO Box 245. |
| Responsible Publisher |
Chief Executive Officer, Akadémiai Kiadó |
| ISSN | 0030-6002 (Print) |
| ISSN | 1788-6120 (Online) |
Monthly Content Usage
| Abstract Views | Full Text Views | PDF Downloads | |
|---|---|---|---|
| Oct 2022 | 0 | 12 | 13 |
| Nov 2022 | 0 | 6 | 7 |
| Dec 2022 | 0 | 15 | 15 |
| Jan 2023 | 0 | 20 | 23 |
| Feb 2023 | 0 | 7 | 7 |
| Mar 2023 | 0 | 5 | 2 |
| Apr 2023 | 0 | 0 | 0 |
Copyright Akadémiai Kiadó
AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Copyright Akadémiai Kiadó AKJournals is the trademark of Akadémiai Kiadó's journal publishing business branch.
Powered by PubFactory